about
Flexible Cyclic Ethers/Polyethers as Novel P2-Ligands for HIV-1 Protease Inhibitors: Design, Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies †Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein–ligand X-ray studiesSelective kainate receptor (GluK1) ligands structurally based upon 1H-cyclopentapyrimidin-2,4(1H,3H)-dione: synthesis, molecular modeling, and pharmacological and biostructural characterizationPyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1.The Ca2+-ATPase (SERCA1) is inhibited by 4-aminoquinoline derivatives through interference with catalytic activation by Ca2+, whereas the ATPase E2 state remains functionalBroad inhibition of plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate.In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitorsMalaria chemotherapy: recent advances in drug development.Identification of novel fluorescent probes preventing PrPSc replication in prion diseases.Structural characterization of Giardia duodenalis thioredoxin reductase (gTrxR) and computational analysis of its interaction with NBDHEX.Disease-modifying anti-Alzheimer's drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation.Rational design of the first difluorostatone-based PfSUB1 inhibitors.Mimicking the intramolecular hydrogen bond: synthesis, biological evaluation, and molecular modeling of benzoxazines and quinazolines as potential antimalarial agents.Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies.Multifunctional cholinesterase and amyloid Beta fibrillization modulators. Synthesis and biological investigation.Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies.Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of potent and Selective iGluR5 modulators.Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the "primer grip" region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants.Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies.Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput dockingPyrrolo[1,5]benzoxa(thia)zepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target.Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents.Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling.Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains.Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase.Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663.Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.Synthesis of dihydroplakortin, 6-epi-dihydroplakortin, and their C10-desethyl analogues.Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characterization.Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships.Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.An efficient approach to chiral C8/C9-piperazino-substituted 1,4-benzodiazepin-2-ones as peptidomimetic scaffolds.
P50
Q27652070-D7ACC7FE-8E63-4E9B-837F-D5E6A08CF086Q27652460-D07DA236-0226-4A5D-910B-1F305709A95DQ27668058-8855281A-98D6-4792-9B59-D5F2A914DB0FQ34108790-5D10111A-A293-464A-9E83-3F33C6FE857BQ34337548-5DCE7947-705A-4945-9338-6C1E6E7C939BQ35516262-2D61E819-E819-47B1-8E1D-A43C8EAD7852Q35677406-9BCCBE3D-0D1C-40BA-82D1-1DBA1516EB1DQ37611650-BAD5E083-4CFD-4937-BC93-777C6422B1A4Q37782360-744A5693-9A67-4532-B3D6-8B603D1C4B86Q38731115-DB5EDE65-92E5-49D8-BF70-F20FEE8FEB2EQ38800833-BD804335-FDDB-47CD-B8D6-C017EA5AF1F2Q38984017-62BCDBBC-C33B-4D8E-B84A-DF32BA0D1E35Q39178883-4401A670-E38D-4E03-993A-AC51487A2034Q39245950-1FAE68B1-3107-41F9-9382-72B2E0C51A70Q39316530-828AD02B-77F2-4813-8225-4FA174A98CA1Q39592595-85D7FB33-9BE6-46C1-92B0-6850AC43EA87Q39778610-A232E96B-ED7D-4CAE-AF76-CFD3BBFEFEA0Q39822950-33DD99B0-4BA6-45B8-B6FA-79C7936E41B0Q39900827-D097885B-B8BE-4536-B301-D250AFD2F65DQ39936822-C6085129-A0EB-4438-976B-649142C3D612Q39973861-597E4ED1-4A0D-4BA6-ADDC-5070D84A12DBQ40012667-34B631B2-C850-4BA4-BFBC-4AB998612CE9Q40177378-44171DDA-3EB9-49CF-92E0-20C2990A581EQ40396694-E789AAA7-9E62-4FF8-94FC-B4A7439DE43BQ40405782-75F3CCD8-6AC9-4343-BE86-2DA5DE34FEADQ40816072-9DCE8126-D745-4B49-97CA-25588AA76424Q41941420-23A340F2-ED72-4CB8-8FBF-2E8D38AFDCC5Q41943023-5C831CCE-BF85-41D8-9D28-E6EB776516ADQ41944796-E50CE3E4-39FD-41F3-A337-105091AC9926Q42712600-9CB5A088-0BB7-4373-835D-8C489F150034Q42873547-E62289F9-4D23-4532-A414-CCE1F6E86B4DQ42993712-FF0B51D7-4CF5-494F-A78D-05F281DA4AB3Q43060339-B806F4EB-4CC0-4652-B602-13749D5BDE89Q43144191-A261FCE7-10E1-4C18-93A0-AEAE0F215005Q43260881-00CDAB3E-5062-44F0-81F7-04FE7DB651C9Q43845249-47241A83-3AA0-4B9A-84D3-59191FC81C7EQ44557226-874EF6D9-52ED-4895-A67A-16D76DB45FEAQ46020291-607D33A9-35BB-44B6-90EA-192610038027Q46146590-A6577EBF-EDCF-44EB-9A16-0CC9ECFA91F3Q46324016-2F6B788B-E391-423A-A832-074EC11A21B5
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Sandra Gemma
@ast
Sandra Gemma
@de
Sandra Gemma
@en
Sandra Gemma
@es
Sandra Gemma
@nl
Sandra Gemma
@sl
type
label
Sandra Gemma
@ast
Sandra Gemma
@de
Sandra Gemma
@en
Sandra Gemma
@es
Sandra Gemma
@nl
Sandra Gemma
@sl
prefLabel
Sandra Gemma
@ast
Sandra Gemma
@de
Sandra Gemma
@en
Sandra Gemma
@es
Sandra Gemma
@nl
Sandra Gemma
@sl
P214
P227
P244
P1053
D-3568-2009
P106
P19
P21
P213
0000 0004 4324 4873
P214
P227
1068299827
P244
nb2014014992
P31
P3829
P496
0000-0002-8313-2417
P569
1973-01-01T00:00:00Z
P734
P735
P7859
lccn-nb2014014992